Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia

This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)

Inclusion Criteria:

• patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD)
• patients must achieve a score of 80 or more on the Full Scale Intelligence Quotient
• child or adolescent patients must be 10 to 16 years old
• must be able to communicate in English
• must be able to swallow capsules
• be reliable to keep appointments for clinic visits and all related tests

Exclusion Criteria:

• patients who weigh less than 25 Kg or greater than 70 Kg
• patients with a history of alcohol or drug abuse on a repeated basis within the past 3 months
• patients with documented history of autism, Asperger's syndrome or pervasive developmental disorder
• females who are pregnant or breastfeeding
• patients with a history of severe allergy to more than one class of medications
• patients with documented history of bipolar I or bipolar II disorder, or psychosis